Invokana Trials Stopped Early Due To Significant Success | Latest News RSS feed

Invokana Trials Stopped Early Due To Significant Success - Latest News


Gilead leukemia drug trial unblinded early due to success

Nov 16 (Reuters) - A late stage trial of a Gilead Sciences drug in previously treated patients with a particular type of leukemia was unblinded early after independent monitors determined the medicine ... read more

Janssen Halts Phase III Kidney Disease Trial Early After Endpoints Were Met

The good news keeps coming for Janssen Pharmaceuticals’ SGLT2 diabetes drug Invokana. Late Monday the company said it was halting its Phase III chronic kidney disease trial early due ... Janssen stopp... read more

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

Johnson & Johnson’s SGLT2 inhibitor Invokana worked ... who co-chaired the trial’s steering committee. “We have accepted the advice of the independent data monitoring committee to stop the CREDENCE tr... read more

Looking for another news?


Dr. Pailey’s Gba-gba Wins Prestigious International Anti-Corruption Award

This was the aim of Dr Pailey, Leverhulme Early ... due-diligence has become a standard of World Bank investigations, and under his guidance the World Bank Preventative Services Unit was created, to e... read more


Remembering John Cassidy, a ‘guiding light’ for NASCAR’s growth

The story of John’s introduction to NASCAR was told often over the years, and it never got old because it was such an important and early ... due to an energy crisis and fuel shortage. The Organizatio... read more

J&J Gets Rid Of Drug For Alzheimer's, But Remains Strong With Oncology Business

Johnson & Johnson abolishes Alzheimer's drug atabecestat in the midst of a safety issue due to liver toxicity ... Johnson & Johnson announced that it would stop the phase 2b/3 trial known as EARLY, wh... read more

Experimental Alzheimer’s Drug Stirs Hope After Early Trials

Results of an early trial ... significant improvement by the study’s first goal of 12 months. However, Biogen recently said the highest dose of 10 milligrams per kilogram of a patient’s body weight, g... read more

CAR T-Cell Therapies Show Durable Responses, New Research Also Explores Combination Therapies to Extend and Enhance Treatment Responses

For example, CAR T cells may stop working in ... international JULIET trial, 19-month results show the overall response rate was 54 percent among 99 patients who were followed for at least three month... read more

Texas cops made more than $50 million in 2017 from seizing people’s property — not everyone was guilty

was so incensed about civil asset forfeiture that she led a press conference early in the 2017 legislative session to announce that a bipartisan coalition of lawmakers was ready to reform the practice ... read more

Reducing Early Elective Deliveries

Every hospital appointed one person to lead the drive to stop early elective deliveries. There were — still are — monthly meetings attended by more than 100 people. Each meeting begins with a success ... read more

Conatus Pharmaceuticals Has A Golden Opportunity With Upcoming Phase 2 Liver Disease Trial Data

The phase 2 POLT-HCV-SVR trial by Conatus is expecting to readout results by Q2 of 2018, this provides an opportunity for investors to get in before the catalyst hits. The phase 2 trial is powered for ... read more

Son's brain tumor diagnosis propels editor to frontiers of medicine

The success of Natan’s treatment provides no guarantees. No one can say how long the medicine will work, whether he should take the drug indefinitely or stop, or whether doing ... therapies in clinica... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us